BIO CEO John Crowley sat down for an exclusive interview that covered tariffs, collaborating with RFK Jr., and investing in ...

Tang Cap­i­tal’s shell com­pa­ny Con­cen­tra Bio­sciences se­cured its first ma­jor deal since late 2023. Al­lakos has agreed ...

Sanofi pays $15M to license Nurix autoimmune program. Sumitomo transfers Asia units. Gilead cuts 149 jobs, Roche 108 in ...

Arie Belldegrun's life sciences venture firm secured a pair of new managing directors after parting ways with two leaders ...

New CDMO Artis BioSolutions has come out of stealth and is snapping up cell and gene therapy manufacturer Landmark Bio for an ...

Edgewise Therapeutics' EDG-7500 shows positive Phase 2 results in heart muscle disease trial, reducing LVOT-G by up to 71%.

Eli Lilly has sued two large compounding pharmacies, alleging they deceive patients and put them at risk with compounded ...

Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal ...

The size and scope of the FDA that began Tuesday won’t be the same as the day nears a brutal conclusion for agency staffers ...

Atsena Therapeutics raises $150M Series C, led by Bain Capital Life Sciences, to advance ATSN-201 gene therapy for X-linked retinoschisis through FDA application.

The European Medicines Agency is looking to simplify the way it approves biosimilars by removing the need for “extensive” clinical data, which would likely cut the cost of entry into the market.

GUBamy, AbbVie-licensed amylin drug from Gubra, shows 7.8% weight loss in Phase 1 trial, vs 2% weight gain with placebo after ...